

C-South, 120 South Saint Joseph St., South Bend, IN.

**Contact:** Keith J. Jasukaitis, Food and Drug Administration, 1560 East Jefferson Ave., Detroit, MI 48207, 313-226-6260, ext. 114, FAX 313-226-3076, or e-mail "kjasukai@ora.fda.gov".

**Registration:** Send registration information (including name, title, firm name, address, telephone, and fax number, and the number of people expected to attend) to the contact person by Friday, October 23, 1998.

If you need special accommodations due to a disability, please notify Keith J. Jasukaitis by October 23, 1998.

Dated: September 11, 1998.

**William K. Hubbard,**

*Associate Commissioner for Policy Coordination.*

[FR Doc. 98-25109 Filed 9-18-98; 8:45 am]

BILLING CODE 4160-01-F

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Food and Drug Administration

#### Advisory Committee for Pharmaceutical Science; Notice of Meeting

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice.

This notice announces a forthcoming meeting of a public advisory committee of the Food and Drug Administration (FDA). The meeting will be open to the public.

**Name of Committee:** Advisory Committee for Pharmaceutical Science.

**General Function of the Committee:** To provide advice and recommendations to the agency on FDA's regulatory issues.

**Date and Time:** The meeting will be held on October 22, 1998, 8:30 a.m. to 5 p.m.

**Location:** Advisory Committee conference room, rm. 1066, 5630 Fishers Lane, Rockville, MD 20852.

**Contact Person:** Kimberly L. Topper or Angie Whitacre, Center for Drug Evaluation and Research (HFD-21), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857-1000, 301-827-7001, or e-mail "Topperk@cder.fda.gov", or FDA Advisory Committee Information Line, 1-800-741-8138 (301-443-0572 in the Washington, DC area), code 12539. Please call the Information Line for up-to-date information on this meeting.

**Agenda:** The committee will discuss: (1) Bioavailability/bioequivalence (BA/BE) issues related to solid oral dosage

forms; (2) progress reports on guidances pertaining to the biopharmaceutical classification system, other BA/BE guidances; and (3) criteria (average, population, and individual) to allow comparison of BE measures/parameters.

**Procedure:** Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Written submissions may be made to the contact person by October 5, 1998. Oral presentations from the public will be scheduled between approximately 1 p.m. and 2 p.m. Time allotted for each presentation may be limited. Those desiring to make formal oral presentations should notify the contact person before October 5, 1998, and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation.

Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app. 2).

Dated: September 11, 1998.

**Sharon Smith Holston,**

*Acting Commissioner of Food and Drugs.*

[FR Doc. 98-25106 Filed 9-18-98; 8:45 am]

BILLING CODE 4160-01-F

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Food and Drug Administration

#### Joint Meeting of the Advisory Committee for Pharmaceutical Science and the Dermatologic and Ophthalmic Drugs Advisory Committee; Notice of Meeting

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice.

This notice announces a forthcoming meeting of a public advisory committee of the Food and Drug Administration (FDA). The meeting will be open to the public.

**Name of Committees:** Advisory Committee for Pharmaceutical Science and the Dermatologic and Ophthalmic Drugs Advisory Committee.

**General Function of the Committee:** To provide advice and recommendations to the agency on FDA's regulatory issues.

**Date and Time:** The meeting will be held on October 23, 1998, 8:30 a.m. to 5 p.m.

**Location:** Advisory Committee Conference Room, rm. 1066, 5630 Fishers Lane, Rockville, MD 20852.

**Contact Person:** Kimberly L. Topper or Tracy Riley, Center for Drug Evaluation and Research (HFD-21), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-827-7001, or e-mail

"Topperk@cder.fda.gov", or FDA Advisory Committee Information Line, 1-800-741-8138 (301-443-0572 in the Washington, DC area), code 12539. Please call the Information Line for up-to-date information on this meeting.

**Agenda:** The committees will discuss: (1) The draft guidance entitled "Topical Dermatological Drug Product NDA's and ANDA's—In Vivo Bioavailability, Bioequivalence, In Vitro Release and Associated Studies;" (2) public comments received on the draft guidance; and (3) additional information.

**Procedure:** Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Written submissions may be made to the contact person by October 5, 1998. Oral presentations from the public will be scheduled between approximately 1 p.m. and 2 p.m. Time allotted for each presentation may be limited. Those desiring to make formal oral presentations should notify the contact person before October 5, 1998, and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation.

Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app. 2).

Dated: September 11, 1998.

**Sharon Smith Holston,**

*Acting Commissioner of Food and Drugs.*

[FR Doc. 98-25107 Filed 9-18-98; 8:45 am]

BILLING CODE 4160-01-F

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Food and Drug Administration

#### Advisory Committee on Special Studies Relating to the Possible Long-Term Health Effects of Phenoxy Herbicides and Contaminants (Ranch Hand Advisory Committee); Notice of Meeting

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice.

This notice announces a forthcoming meeting of a public advisory committee of the Department of Health and Human